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Abstract
Background: Cardiovascular disease is one of major problems in developed and developing 
countries. Atherosclerosis process begins with endothelial dysfunction. Lipoprotein is important 
factor in atherogenesis. Previous study stated that about 50% of cardiovascular events happened 
in individuals with normal or low LDL, therefore LDL plasma level alone is not enough to identify 
individuals with major adverse cardiac events. Individuals with small dense LDL predominant 
have 3 times fold to have cardiovascular risk. The goal of this study is to know whether the level 
of sdLDL has impact on in hospital major adverse cardiac events (MACE) of acute coronary 
syndrome patients.
Methods: This was a cross sectional  study, enrolling patients with acute coronary syndrome 
admitted and hospitalized in ICCU of Dr.Sardjito Hospital since September of 2013 until June 
2015. The small dense LDL (sdLDLD) level was measured with previous formula using routine 
blood lipid component. Major adverse cardiac events (MACE) were determined upon observation 
during horpitalisation and defi ned as death, reinfarction, cardiogenic shock, acute heart failure, 
ventricular tachycardia or ventricular fi brillation, prolonged angina pain, and the need for immediate 
coronary intervention. 
Results: There were 159 patients with mean age 60.80 ± 9.8 years involved in this study. One 
hundred eighteen (118) or 73% of patients were male. The mean of sdLDL level in patients with 
MACE was 108.34 ± 37.94 g/dl and mean sdLDL level in patients without MACE was 105.54 ± 43.10 
g/dl. The level of sdLDL  in patients without MACE was lower than patients with MACE (p=0.705). 
In this study we found the cut- off sdLDL level is ≥ 108.085 for higher sdLDL level and < 108.085 
for lower sdLDL level. The higher sdLDL level have the prevalence ratio of 1.25 to develop MACE, 
however the value was not statistically signifi cant.
Conclusion: The sdLDL level did not correlate with MACE in hospitalised patients with acute 
coronary syndrome. 
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disease that is caused by narrowing of the lumen 
of the coronary arteries due to atherosclerosis 
of the coronary artery wall, causing decreased 
blood fl ow and oxygen supply to the myocardium 
disorders.2,3,4 In the course of the disease, CHD 
can be progressive and often changes suddenly 
from a stable condition into an acute state 
known as acute coronary syndrome (ACS). This 
syndrome consists of unstable angina pectoris, 
Non ST-Segment elevation myocardial infarction 
(NSTEMI), and ST segment elevation myocardial 
infarction (STEMI).
The process of atherosclerosis begins with 
endothelial dysfunction. Endothelial function is 
to maintain the balance between vasodilation 
and vasoconstriction, inhibition and stimulation, 
proliferation and migration of smooth muscle 
Introduction
Cardiovascular disease is one of the major 
health problems in developed and developing 
countries. The disease is becoming the number 
one cause of death in the world each year. More 
than 3 million of these deaths occur before the age 
of 60 years. Deaths caused by heart disease of 
blood vessels, especially coronary heart disease 
and stroke is expected to continue to increase to 
23.3 million deaths in 2030.1
In Indonesia, cardiovascular disease is on 
the increase and will provide loads of morbidity, 
disability and socio-economic burden for families 
of patients, communities, and countries. The 
prevalence of heart failure disease in Indonesia 
in 2013 is based on the doctor’s diagnosis at 
0:13%.1 Coronary heart disease(CHD) is a 
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cells, as well as between thrombogenesis and 
fi brinolysis. Infl ammation plays a role in endothelial 
dysfunction.5 One of the advances in medicine 
that is quite important is the identification of 
major risk factors for cardiovascular disease 
events. Lipoprotein plays an important role 
in atherogenesis. Low Density Lipoproteins-
cholesterol (LDL-C) is the main target in CHD 
prevention guidelines. Plasma levels of LDL-C 
alone is not enough to identify an individual with 
cardiovascular events, because on average 50% 
of cardiovascular events occur in individuals with 
normal LDL levels even lower.6
Low density lipoprotein is composed of 
heterogeneous particles that differ in terms of 
density, size and chemical composition. Individuals 
with a predominance of small dense LDL (sdLDL) 
had a 3-fold increased risk of cardiovascular 
disease.7 Currently, sdLDL has been underlined as 
new markers of potential cardiovascular disease 
risk in Western populations and Japan, which have 
high levels of LDL-C is relatively low.7 In patients 
with ACS, high levels of sdLDL have more major 
cardiovascular events because macrophages 
containing much sdLDL had higher chemotactic 
activity and higher proteolitic so that conditions 
make the plaque become more unstable.8
Major adverse cardiovascular events 
(MACE) during hospitalization remains a problem 
encountered in the management of patients with 
ACS. Several risk factors have been identifi ed 
as factors related to adverse events during 
hospitalization. Small dense low-density lipoprotein 
has been identifi ed as a risk factor for coronary 
artery disease, whether it can be used to assess 
the MACE during hospitalization in acute coronary 
syndrome is still not fully known, moreover sdLDL 
research on the acute phase of the ACS is still 
very limited.
The aim of this study is to investigate 
whether high levels of sdLDL have a relationship 
with MACE during hospitalization in patients with 
ACS. The author’s knowledge there has been no 
research on the relationship between the sdLDL 
levels after acute coronary syndrome with MACE, 
especially during hospitalization.
Methods
This study was an observational study. The 
study design was cross-sectional study, which 
assessed the relationship between levels of sdLDL 
during hospitalisation with the outcomes of major 
adverse cardiovascular events (MACE). The study 
started from September 2013 until minimal sample 
size requirement completed. 
The subjects were patients with ACS and 
hospitalized in the ICCU of Dr. Sardjito General 
Hospital Yogyakarta, Indonesia using sequential 
/ consecutive enrolling methods.  The inclusion 
criteria for this study were: patients with ACS 
who were diagnosed according to the criteria 
of the guidelines of the American College of 
Cardiology Foundation (ACCF) / American Heart 
Association (AHA) 2013, patients aged 30-80 
years, and agreed to participate in the study. The 
exclusion criteria were patients with a history: 
Stage V chronic renal failure, chronic heart failure, 
and liver cirrhosis, patients with comorbidities: 
acute stroke, acute infections, sepsis and venous 
or arterial thromboembolism and patients with 
malignancy. Subjects were observed during 
intensive hospitalisation in ICCU. The MACE 
consisted of death, reinfarction, cardiogenic shock, 
acute heart failure, ventricular tachycardia or 
ventricular fi brillation (VT / VF), prolonged angina 
pain, as well as the conditions that indicate the 
need for immediate coronary intervention.
The independent variable was the level of 
sdLDL and dependent variable of this study was 
MACE during hospitalisation in ICCU. An sdLDL 
level was calculated by the formula9 : sdLDL 
= 0.94 total cholesterol – 0.94 HDL – 0.19 TG/
Apo-B – 0.09 chol + 0.09 HDL – 0.08 TG. HDL 
was high density lipoprotein, TG was triglyceride 
and Apo-B was apolipoprotein B. The unit value 
was set in mg/dL. 
The statistical analysis was performed by 
using the chi-square test. Data analysis was 
performed with SPSS version 22 package. The 
research was conducted after achieving an 
approval from the Ethics Committee of Research, 
Faculty of Medicine, Universitas Gadjah Mada.
Result
The number of subjects in this the study 
was 159 patients and composed of 73.8% male, 
25.6% female with mean age of 60.8 years. The 
characteristics of the study subjects was shown 
in table 1.
The acute coronary syndrome classifi cation 
was STEMI (61%), NSTEMI (18.2%) and unstable 
angina (20.8%). The proportion of subjects with 
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terms of demographics, disease history, previous 
CHD risk factors, clinical spectrum of ACS and 
a standard lipid parameters. The mean CKMB 
and creatinine were higher in the MACE group 
compared to the group without MACE, while the 
average use of beta blockers in the MACE group 
was lower than the group without MACE (p <0.05) 
(table 2). 
This was consistent with the theory that 
high levels of cardiac enzymes such as CKMB 
or troponin I, the MACE was higher as compared 
to those with normal cardiac enzyme levels. 
The higher the levels, the worst  prognosis 
and increased MACE. This was because that 
the higher cardiac enzymes were detected in 
laboratory indicate  extensive damaged of heart 
muscle.10 Cardiovascular events was higher in 
patients with chronic kidney disease (CKD), and 
will increase the incidence of cardiovascular 10-
30 times higher than patients who did not suffer 
from CKD.11
Figure 1. Receiver-operating characteristics curve 
(ROC) of sdLDL level value based on MACE during 
hospitalization in subjects with ACS
Levels of LDL in the non MACE and MACE 
groups were higher than the normal reference 
value, indicating a high risk for developing CHD. 
The sdLDL levels was 108.34 ± 37.94 mg/dL in the 
MACE group and 105.54 ± 45.97 mg/dL in the non 
MACE group. The sdLDL level at MACE group was 
higher than the non MACE group but there was 
no statistically signifi cant difference between two 
groups (p = 0.705). In this study, we need a cut-off 
point value to determine sdLDL level in patients 
risk factors for diabetes mellitus was 50 patients 
(31.4%), hypertension 118 (74.2%), smokers 
90 patients (56.6%), CHD history of 46 patients 
(28.9%), history CHD in a family of 4 patients 
(2.5%) and dyslipidemia 48 (30.2%).
Among 159 subjects, 44 patients have 
MACE (MACE group) and 115 patients did not 
experience MACE (group without MACE). In the 
group of MACE there were 10 (22.7%) patients 
died, 3 (6.8%) reinfarction, 16 (36.4%) patients 
had Killip II-IV (acute heart failure), 4 (7.2%) 
patients had ventricular tachycardia/ventricular 
fi brillation requiring defi brillation or intravenous 
antiarrhythmic drugs, 52 (32.7%) patients had 
to be done PCI immediately because of medical 
indications, and 1 (2.3%) patient experienced 
acute stroke during hospitalization.
Statistically, the characteristics of the two 
groups there was no significant difference in 
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with ACS to predict MACE. Based on the receiver 
operating characteristic curve (ROC) the cut-off 
value was 108.08 mg/dL (Figure 1). 
Subjects with sdLDL level ≥ 108.08 mg/
dL belong to the group of high sdLDL and those 
with sLDL level < 108.08 mg/dL were classifi ed 
in the group of low sdLDL. Table 3 showed that 
high levels of sdLDL had the prevalence ratio of 
1.25 for the MACE among patients with ACS, 
however there were no statistically signifi cance 
(p = 0392).
The level of sdLDL is a strong predictor of 
CHD event as compared to other parameters. 
Nevertheless, there has been no previous study 
that compared the levels sdLDL between MACE 
group and without MACE group patients with ACS. 
In the univariate analysis of this study, it was found 
that a history of previous coronary heart disease, 
smoking, clinical spectrum, gender, heparin, 
beta blockers, statins, PCI, CKMB and creatinine 
impacted MACE.
Tabel 3. Prevalence ratio of MACE in high sLDL  level among 
patients with ACS
MACE
P value PR (95 % CI)
n %
High sdLDL level
(≥ 108.08 mg/dL) 24 54.5
0.392 1.25 (0.75 – 2.066)
Low sdLDL level 
(< 108.08 mg/dL) 20 45.4
sdLDL : small dense Low density Lipoprotein, MACE: Major Adverse 
Cardiac Event, PR : Prevalence ratio, 95% CI : 95% Confidence 
Interval
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Results of multivariate analysis showed that 
the previous history of CHD, smoking behaviour, 
PCI treatment, increased CKMB level, and 
increased creatinine level were independently 
predict MACE. Level of sdLDL did not associate 
with occurence of MACE. Results of the analysis 
were shown in table 4.
Tabel 4. Multivariate analysis of variables that 
affect the MACE
Variable OR (95% CI) p
Previous history of CHD 3.53 (1.16-10.74) 0.026
Smoking 3.06 (1.27-7.39) 0.013
Clinical spectrum 1.09 (0.33- 3.67) 0.886
sdLDL 0.45 (0.18-1.12) 0.656
Heparin 1.81 (0.49- 6.57) 0.368
Beta blockers 2.43 (0.92-6.45) 0.073
Statins 0.69 (0.07-6.32) 0.741
PCI 0.09 (0.01-0.88) 0.039
CKMB 3.58 ( 1.48- 8.64) 0.005
Creatinine 6.94 (2.83-16.97) 0.000
CHD: Coronary Heart Disease, sdLDL: small dense 
Low Density Lipoprotein, PCI: Percutaneous Coronary 
Intervention, CKMB: creatine kinase isoenzyme MB, 
OR: odds ratio, 95% CI : 95% Confi dence Interval, 
signifi cant if p> 0.05
Discussion
The basic characteristics of the two groups 
did not differ statistically signifi cant in terms of 
demographics, disease history and previous CHD 
risk factors, clinical spectrum of ACS and lipid 
parameters. This indicated that the results were 
not infl uenced by general characteristics of the 
study subjects. In this study, a cut-off point sdLDL 
concentration is 108.08 mg/dl. Value ≥ 108.08 
mg/dL is considered high and <108 085 g / dl 
categorized as low between group. From previous 
studies the normal value sdLDL was 15.45 ± 5 mg/
dL in healthy individual.12 The level of sdLDL is also 
divided into high risk of CHD if sdLDL levels > 30 
mg/dl, intermediates risk if sLDL level 21-30 mg/dl 
and the optimal range is < 21 mg/dl.13 Lipoprotein 
and apolipoprotein abnormalities, especially sdLDL 
can cause endothelial dysfunction by interfering 
with the balance related vasodilation function of 
nitrite oxide, prostacyclin and thromboxane A2. 
In addition, they inversely correlated with HDL-
platelet thrombus formation. Low HDL, therefore 
low levels of apoA-1, may increase the activity of 
platelet activating factor and initiated the thrombus 
formation.14,15Other variables were statistically 
signifi cant related to the occurrence of MACE is 
CKMB levels upon hospital admission (p = 0.007). 
It is known that high levels of CKMB correlated to 
the size of myocardial infarction occurring, and 
the more extensive infarction, ventricular function 
is also getting bad result in increased risk MACE 
10. The use of beta-blockers for the treatment 
MACE group was lower than that non- MACE 
group (63.6% vs 80 %) and the proportion of 
this difference was statistically signifi cant (p = 
0.032). In the ESC guidelines, beta blockers are 
recommended for immediate given to patients with 
ACS because it can reduce mortality.16 In another 
study, beta blockers do not have the effect in 
lowering mortality, but can reduce the incidence 
of recurrent myocardial infarction and angina.17 In 
this study, the use of beta blockers was lower in the 
MACE group and may affect the outcome of the 
study. Beta blockers are recommended for patients 
with UAP or NSTEMI, especially if there are 
hypertension and / or tachycardia. The proportion 
of revascularization with PCI were signifi cantly 
higher in the group MACE compared to the group 
without MACE (50% vs 26.8%) (p = 0.021), 
possibly because the group MACE initial condition 
was worse so that more coronary intervention 
performed as compared to group without MACE. 
In accordance with previous theories that PCI 
procedures can reduce MACE. The strategy of 
invasive angiography is aimed at patients with high 
to very high risk and in this guideline is a class IA 
recommendation.18 The result of the multivariate 
analysis showed that previously history of CHD 
increased the risk of MACE. This may be due to the 
presence of previous abnormalities of heart muscle 
which can aggravate the clinical condition of the 
patient during acute events and would increase 
the occurrence of MACE.
Smoking is also a factor that is increasing 
the incidence of MACE in this study. Multivariate 
analysis showed smoking can increase the 
incidence of MACE. Previous studies have shown 
that smoking damages blood vessels and affects 
all phases of atherosclerosis, since endothelial 
dysfunction until the ACS. Smoking toxin 
components and mechanisms involved in the onset 
of cardiovascular dysfunction is unclear, however 
smoking increases infl ammation, thrombosis, and 
oxidation of LDL. Previous research data also 
showed exposure to smoking increases oxidative 
stress thus becoming potential mechanisms that 
initiate cardiovascular dysfunction.19 
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The results are consistent with the PCI as 
actions that provide good clinical outcomes for 
patients with ACS. Results of this study are also 
consistent with other research that states that the 
PCI decrease the incidence of MACE within 30 
days.20 Another factor that affects the MACE in this 
study is CKMB. Results of multivariate conveniently 
indicates CKMB provide almost fourfold the risk 
of the occurrence of MACE in ACS patients in 
this study. The CKMB is a marker of myocardial 
infarction. Patients with CKMB increase or more 
than 3 times the normal value has damaged blood 
vessels more and more likely to have coronary 
lesions type C, an average of more and longer 
stents were installed, as well as having clinical 
success are lower, so MACE more in patients with 
higher CKMB.21 The study also found that CKMB 
is an independent factor affecting MACE, where 
MACE are more prevalent in the group with higher 
CKMB. In this study, creatinine also give effect to 
the MACE independently. 
Several limitation were found in this study. 
Firstly, the varying levels of triglycerides and its 
association with glucose intolerance will affect 
the levels of sdLDL. In patients with glucose 
intolerance, sdLDLnya levels will be higher. This 
study could not detect the presence of glucose 
intolerance. Second, the study also did not include 
several confounding factors that may affect the 
lipid profile and insidence of MACE, such as 
previous medication, TIMI score, GRACE score, 
extent and location of infarction, previous ejection 
fraction, so the MACE incident analysis in this 
study is less detail.
Conclusion
From the results of this study, it was 
concluded that the levels of sdLDL, calculated 
from blood lipid value, did  not associated with risk 
of MACE in patients hospitalised with ACS. 
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